AP
VRTX icon

Adero Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Adero Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$669K Buy
1,380
+33
+2% +$15.4K 0.04% 110
2024
Q4 		$542K Buy
1,347
+5
+0.4% +$2.32K 0.04% 116
2024
Q3 		$624K Buy
1,342
+29
+2% +$13.9K 0.04% 109
2024
Q2 		$615K Buy
1,313
+37
+3% +$16.1K 0.04% 104
2024
Q1 		$533K Buy
1,276
+4
+0.3% +$1.69K 0.04% 109
2023
Q4 		$518K Buy
1,272
+68
+6% +$25.1K 0.04% 103
2023
Q3 		$419K Buy
+1,204
New +$421K 0.04% 117

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adero Partners's VRTX Position: Q1 2025 in Review

Adero Partners increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2025, buying an estimated $15.4K and bringing the position to 1,380 shares worth $669K. The position accounts for 0.04% of the portfolio, ranked #110.

Adero Partners first reported a position in VRTX in Q3 2023 and has held it in 7 quarters since. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Adero Partners held 1,380 shares of Vertex Pharmaceuticals worth $669K as of Q1 2025.
  • Adero Partners bought 33 Vertex Pharmaceuticals shares in Q1 2025, an estimated $15.4K.
  • Vertex Pharmaceuticals made up 0.04% of Adero Partners's portfolio in Q1 2025, its #110 holding.
  • Adero Partners first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Adero Partners's 13F filing for Q1 2025, filed 17 Apr 2025.